Abstract
Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Current Pharmaceutical Biotechnology
Title: The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems
Volume: 6 Issue: 1
Author(s): O. Kayser, A. Lemke and N. Hernandez-Trejo
Affiliation:
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Abstract: Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Export Options
About this article
Cite this article as:
Kayser O., Lemke A. and Hernandez-Trejo N., The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems, Current Pharmaceutical Biotechnology 2005; 6 (1) . https://dx.doi.org/10.2174/1389201053167158
DOI https://dx.doi.org/10.2174/1389201053167158 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
GABAA Receptor Channel Pharmacology
Current Pharmaceutical Design Meet our Editorial Board Member
Current Cancer Therapy Reviews Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms
Current Neuropharmacology Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures
Current Topics in Medicinal Chemistry Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Development of an HPLC-UV Method for Quantification of Stattic
Current Pharmaceutical Analysis High Podophyllotoxin Producing Hairy Root Line of Linum Album: Influence of Carbohydrates, Temperature and Photoperiod
Current Biotechnology Recent Progress in Radiofluorination of Peptides for PET Molecular Imaging
Current Organic Synthesis Anticancer Potential of Pulicaria crispa Extract on Human Breast Cancer MDA-MB-231 Cells
Letters in Drug Design & Discovery Longitudinal Melatonin Production in Female Laboratory Rats During 1997-2006: Possible Modulatory Effects of Changing Solar Activity
Current Aging Science How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic Ion Fluxes and Cancer (Guest Editors: Luca Munaron and Annarosa Arcangeli)]
Recent Patents on Anti-Cancer Drug Discovery Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics The Key microRNAs Regulated the Development of Non-small Cell Lung Cancer by Targeting TGF-β-induced epithelial–mesenchymal Transition
Combinatorial Chemistry & High Throughput Screening An Unexpected Diagnosis of Liver Metastases on a Bone Scan
Current Radiopharmaceuticals Garlic [Allium sativum]: A Review of its Potential Use as an Anti-Cancer Agent
Current Cancer Drug Targets High Order Texture-Based Analysis in Biomedical Images
Current Medical Imaging Assessment and Management of the Adnexal Mass in the Pediatric Population
Current Women`s Health Reviews Structure-Based Design of Novel Anti-Cancer Agents TargetingAurora Kinases
Current Medicinal Chemistry - Anti-Cancer Agents